Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

February 16, 2021February 16, 2021

Erleada-ADT Combo Found to Prolong Survival, Delay Cancer Worsening

News

When given in combination with androgen deprivation therapy or ADT, Erleada (apalutamide) significantly prolonged the lives of men with metastatic hormone-sensitive prostate cancer (mHSPC) — without compromising their quality of ... Read more

January 14, 2021January 14, 2021

Nubeqa Prescribing Information Updated With New Survival Data

News

The prescribing information for Nubeqa (darolutamide) — used to treat men with prostate cancer that has not spread to other parts of the body — will be updated to include ... Read more

December 1, 2020December 1, 2020

FDA Approves FoundationOne Liquid CDx as Companion Test for Lynparza in mCRPC Patients

News

The U.S. Food and Drug Administration (FDA) has approved FoundationOne Liquid CDx to be used as a companion diagnostic test to identify men with metastatic castration-resistant prostate cancer (mCRPC) who ... Read more

October 13, 2020October 13, 2020

New AI Algorithm Can Accurately Identify, Grade Prostate Cancer

News

A new artificial intelligence (AI) algorithm has been developed that can accurately detect and grade prostate cancer, using slide images from patient core needle prostate biopsies, a study reports. The ... Read more

September 29, 2020September 29, 2020

Most nmCRPC Patients Can Safely Take Full Dose of Nubeqa, Trial Analysis Shows

News

Nearly all men with non-metastatic castration-resistant prostate cancer (nmCRPC) received the full planned dose of Nubeqa (darolutamide) tablets while participating in the ARAMIS Phase 3 trial, and few required dose ... Read more

September 17, 2020September 17, 2020

NCI Grant to Probe Link Between Prostate Cancer and Fatty Cells in Bone Marrow

News

A five-year grant of more than $2 million from the National Cancer Institute (NCI) will support research investigating the link between prostate cancer cells and the fatty cells — adipocytes — found ... Read more

September 8, 2020September 8, 2020

IPCR Launches Exercise Video Series for Prostate Cancer Patients

News

The Institute for Prostate Cancer Research (IPCR), a collaborative effort between the Fred Hutchinson Cancer Research Center and UW Medicine, has launched a video series of exercises especially designed to ... Read more

August 11, 2020August 11, 2020

Dosing Begins in Trial of PET Imaging Agent to Detect Prostate Cancer’s Return

News

The first patients have been injected in a Phase 3 trial investigating the safety and performance of Blue Earth Diagnostics‘ imaging agent rhPSMA-7.3 (18F) in detecting prostate cancer in men with ... Read more

July 23, 2020July 23, 2020

New Risk Calculator May Help Men With High PSA Decide on Having Prostate Biopsy

News

A new risk calculator may help men with high levels of prostate-specific antigen (PSA) — a marker of prostate cancer — to decide if they should undergo a prostate biopsy ... Read more

July 15, 2020July 15, 2020

Laser Focal Therapy Effective, Causes Few Side Effects, 10-Year Trial Data Shows

News

Image-guided laser focal therapy is as effective as radical prostate removal surgery at treating men with localized prostate cancer, without the added risks of infection, incontinence, and erectile dysfunction, according ... Read more